Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double‐blind treatment phase of a randomized placebo‐controlled trial of tocilizumab safety and prevention of structural joint damage at one year

Objective To assess the efficacy and safety of tocilizumab plus methotrexate (MTX) versus MTX alone in preventing structural joint damage and improving physical function and disease activity in patients with moderate‐to‐severe rheumatoid arthritis and inadequate responses to MTX. Methods A total of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2011-03, Vol.63 (3), p.609-621
Hauptverfasser:	Kremer, Joel M., Blanco, Ricardo, Brzosko, Marek, Burgos‐Vargas, Ruben, Halland, Anne‐Marie, Vernon, Emma, Ambs, Petra, Fleischmann, Roy
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antirheumatic Agents - administration & dosage Antirheumatic Agents - adverse effects Arthritis, Rheumatoid - diagnostic imaging Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - pathology Biological and medical sciences Bones, joints and connective tissue. Antiinflammatory agents Diseases of the osteoarticular system Double-Blind Method Drug therapy Female Humans Immunomodulators Inflammatory joint diseases Joints - pathology Male Medical sciences Methotrexate Methotrexate - administration & dosage Methotrexate - adverse effects Middle Aged Pharmacology. Drug treatments Placebos Radiography Rheumatoid arthritis Severity of Illness Index Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!